Developing a new tool for measuring radiation doses in cancer treatment
3D In vivo dosimetry for FLASH proton therapy
This study is working on a new device that will help doctors measure radiation levels during a special cancer treatment called proton FLASH therapy, making sure tumors get the right dose while protecting healthy tissue, and it aims to be ready for use in hospitals in the next 5-10 years.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California-Irvine NIH-funded |
| Lab location | 1 site (Irvine, United States) |
| Project ID | NIH-10849547 on NIH RePORTER |
What this research studies
This research focuses on creating a new type of dosimeter that can accurately measure radiation doses during proton FLASH therapy, a cutting-edge cancer treatment that delivers high doses of radiation quickly. The project aims to ensure that the right amount of radiation is delivered to tumors while minimizing damage to surrounding healthy tissues. By forming a collaborative team of experts from various fields, the research seeks to bring this innovative dosimeter into clinical use within the next 5-10 years, addressing a critical need in cancer care.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients who are undergoing proton FLASH therapy.
Not a fit: Patients who are not receiving radiation therapy or those with conditions that do not involve proton FLASH therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective cancer treatments by improving the precision of radiation delivery.
How similar studies have performed: While the approach of using protoacoustic imaging for dosimetry is innovative, similar research in radiation therapy has shown promise in improving treatment accuracy.
Where this research is happening
Irvine, United States
- University of California-Irvine — Irvine, United States (Active)
Researchers
- Principal investigator: Xiang, Liangzhong Shawn — University of California-Irvine
- Study coordinator: Xiang, Liangzhong Shawn
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.